



OPEN ACCESS

APPROVED BY

Michael Heinrich,
University College London,
United Kingdom

*CORRESPONDENCE

Frontiers Editorial Office,
✉ research.integrity@frontiersin.org

RECEIVED 05 September 2023

ACCEPTED 05 September 2023

PUBLISHED 08 September 2023

CITATION

Frontiers Editorial Office (2023),
Retraction: Xianglian pill suppresses
inflammation and protects intestinal
epithelial barrier by promoting autophagy
in DSS induced ulcerative colitis mice.
Front. Pharmacol. 14:1289227.
doi: 10.3389/fphar.2023.1289227

COPYRIGHT

© 2023 Frontiers Editorial Office. This is
an open-access article distributed under
the terms of the [Creative Commons
Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use,
distribution or reproduction in other
forums is permitted, provided the original
author(s) and the copyright owner(s) are
credited and that the original publication
in this journal is cited, in accordance with
accepted academic practice. No use,
distribution or reproduction is permitted
which does not comply with these terms.

Retraction: Xianglian pill suppresses inflammation and protects intestinal epithelial barrier by promoting autophagy in DSS induced ulcerative colitis mice

Frontiers Editorial Office*

A Retraction of the Original Research Article

[Xianglian pill suppresses inflammation and protects intestinal epithelial barrier by promoting autophagy in DSS induced ulcerative colitis mice](#)

by Wang B, Gong Z, Zhan J, Yang L, Zhou Q and Yuan X (2021). *Front. Pharmacol.* 11:594847. doi: [10.3389/fphar.2020.594847](https://doi.org/10.3389/fphar.2020.594847)

The journal retracts the 2021 article cited above.

Following publication, concerns were raised regarding the validity of the data in the article. The authors failed to provide the raw data or a satisfactory explanation during the investigation, which was conducted in accordance with Frontiers' policies. Given the concerns, and the lack of raw data, the editors no longer have confidence in the findings presented in the article.

This retraction was approved by the Chief Editors of Frontiers in Pharmacology and the Chief Executive Editor of Frontiers. The authors agree to this retraction.